These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

630 related articles for article (PubMed ID: 23276521)

  • 21. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
    Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
    Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection.
    Choi J; Lim H; Nam DK; Kim HS; Cho DY; Yi JW; Kim HC; Cho YK; Kim MW; Joo HJ; Lee KB; Kim KB
    Br J Cancer; 2001 Jan; 84(2):186-92. PubMed ID: 11161374
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
    André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
    J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunohistochemical evaluation of thymidylate synthase (TS) and p16INK4a in advanced colorectal cancer: implication of TS expression in 5-FU-based adjuvant chemotherapy.
    Kamoshida S; Matsuoka H; Ishikawa T; Maeda K; Shimomura R; Inada K; Tsutsumi Y
    Jpn J Clin Oncol; 2004 Oct; 34(10):594-601. PubMed ID: 15591457
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials.
    Zaanan A; Shi Q; Taieb J; Alberts SR; Meyers JP; Smyrk TC; Julie C; Zawadi A; Tabernero J; Mini E; Goldberg RM; Folprecht G; Van Laethem JL; Le Malicot K; Sargent DJ; Laurent-Puig P; Sinicrope FA
    JAMA Oncol; 2018 Mar; 4(3):379-383. PubMed ID: 28983557
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Defective Mismatch Repair Status was not Associated with DFS and OS in Stage II Colon Cancer Treated with Adjuvant Chemotherapy.
    Kim JE; Hong YS; Kim HJ; Kim KP; Lee JL; Park SJ; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Hoon KJ; Kim TW
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S630-7. PubMed ID: 26271397
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
    Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
    Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population.
    Huang ZH; Hua D; Li LH
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):911-8. PubMed ID: 18704422
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic and predictive value of thymidylate synthase expression in primary colorectal cancer.
    Karlberg M; Ohrling K; Edler D; Hallström M; Ullén H; Ragnhammar P
    Anticancer Res; 2010 Feb; 30(2):645-51. PubMed ID: 20332484
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy.
    Li P; Fang YJ; Li F; Ou QJ; Chen G; Ma G
    Br J Cancer; 2013 Apr; 108(6):1238-44. PubMed ID: 23481186
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study.
    Garrity MM; Burgart LJ; Mahoney MR; Windschitl HE; Salim M; Wiesenfeld M; Krook JE; Michalak JC; Goldberg RM; O'Connell MJ; Furth AF; Sargent DJ; Murphy LM; Hill E; Riehle DL; Meyers CH; Witzig TE;
    J Clin Oncol; 2004 May; 22(9):1572-82. PubMed ID: 15117979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thymidylate synthase expression in colon carcinomas with microsatellite instability.
    Sinicrope FA; Rego RL; Halling KC; Foster NR; Sargent DJ; La Plant B; French AJ; Allegra CJ; Laurie JA; Goldberg RM; Witzig TE; Thibodeau SN
    Clin Cancer Res; 2006 May; 12(9):2738-44. PubMed ID: 16675565
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low thymidylate synthase expression in the primary tumor predicts favorable clinical outcome in resected gastric cancer patients treated with adjuvant tegafur.
    Grau JJ; Domingo-Domenech J; Morente V; Pera M; Garcia-Valdecasas JC; Fuster J; Bombí A; Mellado B; Albanell J; Gascón P
    Oncology; 2004; 66(3):226-33. PubMed ID: 15218314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study.
    Allegra CJ; Paik S; Colangelo LH; Parr AL; Kirsch I; Kim G; Klein P; Johnston PG; Wolmark N; Wieand HS
    J Clin Oncol; 2003 Jan; 21(2):241-50. PubMed ID: 12525515
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment.
    Dotor E; Cuatrecases M; Martínez-Iniesta M; Navarro M; Vilardell F; Guinó E; Pareja L; Figueras A; Molleví DG; Serrano T; de Oca J; Peinado MA; Moreno V; Germà JR; Capellá G; Villanueva A
    J Clin Oncol; 2006 Apr; 24(10):1603-11. PubMed ID: 16575011
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of thymidylate synthase expression in lymph node metastases of colorectal cancer can improve the prognostic information.
    Ohrling K; Edler D; Hallström M; Ragnhammar P; Blomgren H
    J Clin Oncol; 2005 Aug; 23(24):5628-34. PubMed ID: 16009948
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.
    Bertagnolli MM; Niedzwiecki D; Compton CC; Hahn HP; Hall M; Damas B; Jewell SD; Mayer RJ; Goldberg RM; Saltz LB; Warren RS; Redston M
    J Clin Oncol; 2009 Apr; 27(11):1814-21. PubMed ID: 19273709
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer.
    Jakob C; Aust DE; Meyer W; Baretton GB; Schwabe W; Häusler P; Becker H; Liersch T
    J Pathol; 2004 Dec; 204(5):562-8. PubMed ID: 15538739
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thymidylate synthase expression in stage II and III colon cancer: a retrospective review.
    Tomiak A; Vincent M; Earle CC; Johnston PG; Kocha W; Taylor M; Maroun J; Eidus L; Whiston F; Stitt L
    Am J Clin Oncol; 2001 Dec; 24(6):597-602. PubMed ID: 11801762
    [TBL] [Abstract][Full Text] [Related]  

  • 40. dUTP nucleotidohydrolase isoform expression in normal and neoplastic tissues: association with survival and response to 5-fluorouracil in colorectal cancer.
    Ladner RD; Lynch FJ; Groshen S; Xiong YP; Sherrod A; Caradonna SJ; Stoehlmacher J; Lenz HJ
    Cancer Res; 2000 Jul; 60(13):3493-503. PubMed ID: 10910061
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.